A Phase I/II Study of ASTX660 in Patients With Relapsed or Refractory T-cell Lymphoma

NCT ID: NCT04362007

Last Updated: 2025-01-15

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 61 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-07-14
• Study Completion Date: 2024-11-30

Brief Summary

Phase 1 (dose-escalation part): Investigate the tolerability and safety of ASTX660 in patients with r/r PTCL and r/r CTCL and determine the recommended dose (RD) for the Phase 2.

Phase 1 (ATLL expansion part): Evaluate the safety of ASTX660 at RD in patients with r/r ATLL.

Phase 2 : Evaluate the efficacy of ASTX660 at RD in patients with r/r PTCL.

Conditions

Relapsed or Refractory Peripheral T-cell Lymphoma(PTCL),Cutaneous T-cell Lymphoma(CTCL),Adult T-cell Leukemia/Lymphoma(ATLL)

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Phase 1 dose-escalation part

Subjects with r/r PTCL and r/r CTCL will receive ASTX660 once a day for 7 consecutive days every other week of each 28-day cycle (ie, \[7 days on/ 7 days off\] ×2; daily dosing on Days 1-7 and 15-21). The starting dose will be escalated stepwise in successive cohorts of 3 to 6 evaluable subjects each (standard 3+3 study design), until the RD is determined.

Group Type: EXPERIMENTAL

ASTX660

Intervention Type: DRUG

Treatment of ASTX660 for r/r PTCL and r/r CTCL

Phase 1 ATLL expansion part

Subjects with r/r ATLL will receive ASTX660 at RD obtained from the Phase 1 part (dose-escalation part) once a day for 7 consecutive days every other week of each 28-day cycle.

Group Type: EXPERIMENTAL

ASTX660

Intervention Type: DRUG

Treatment of ASTX660 for r/r ATLL

Phase 2

Subjects with r/r PTCL will receive ASTX660 at RD obtained from the Phase 1 part (dose-escalation part) once a day for 7 consecutive days every other week of each 28-day cycle.

Group Type: EXPERIMENTAL

ASTX660

Intervention Type: DRUG

Treatment of ASTX660 for r/r PTCL

Interventions

ASTX660

Treatment of ASTX660 for r/r PTCL and r/r CTCL

Intervention Type: DRUG

ASTX660

Treatment of ASTX660 for r/r ATLL

Intervention Type: DRUG

ASTX660

Treatment of ASTX660 for r/r PTCL

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Patients with T-cell lymphoma with histological diagnosis based on WHO classification (2017)

2. Patients with evaluable lesions.

3. Patients with ECOG PS score of 0 or 1.

4. Patients with adequate organ functions as shown below.

• AST and ALT ≤ 2.0 × ULN (≤ 3.0 × ULN if liver infiltration is present)
• Total bilirubin ≤ 1.5 × ULN
• ANC ≥ 1,000/mm3 (≥ 750/mm3 if bone marrow infiltration is present)
• Platelet count 50,000/mm3 (25,000/mm3 if bone marrow infiltration is present)
• Serum creatinine ≤ 1.5 × ULN or creatinine clearance ≥ 50 mL/min
• Amylase and lipase ≤ 1.0 × ULN

Exclusion Criteria

1. Patients with active infection requiring treatment with antibiotics, antifungals, or antivirals

2. Patients with heart disease that meets the followings:

1. LVEF of < 50% by echocardiography or MUGA scan

2. Congestive heart failure (NYHA classification III or IV)

3. Uncontrolled heart disease including unstable angina pectoris or hypertension considered to require hospitalization within last 3 months (90 days)

4. Complete left bundle branch block, III degree (complete) atrioventricular block, use of pacemaker, history or complication of poorly controlled arrhythmia requiring treatment

5. History or complication of long QT syndrome

6. History or complication of ventricular arrhythmia requiring active treatment

7. Corrected QT interval of ≥ 470 msec based on 12-lead ECG performed at the screening

8. Concern on increased cardiac risk by participating in the study based on medical judgment

3. Patients receiving the following treatment for the primary disease prior to the initial dose of study drug

1. Chemotherapy or radiotherapy within last 3 weeks

2. Skin directed therapy including local treatment or phototherapy within last 3 weeks

3. Treatment with monoclonal antibody within last 4 weeks

4. Treatment with other study drugs or study treatment within last 3 weeks or 5 half-lives, whichever is longer

4. Patients with prior allogeneic stem cell transplantation, or autologous stem cell transplantation within 14 weeks prior to the day of initial dose of study drug

5. Patients who have received corticosteroids at a dose exceeding a prednisone equivalent dose of 10 mg/day within 3 weeks prior to the initial dose of study drug.

6. Patients with Inadequately controlled diabetes mellitus

• Minimum Eligible Age: 20 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Otsuka Pharmaceutical Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Nobuhito Sanada

Role: STUDY_DIRECTOR

Otsuka Pharmaceutical Co., Ltd.

Locations

Yamagata University Hospital

Yamagata, , Japan

Countries

Japan

Other Identifiers

JapicCTI-205258

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

401-102-00001

Identifier Type: -

Identifier Source: org_study_id